PI3Kδ and primary immunodeficiencies View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-09-12

AUTHORS

Carrie L. Lucas, Anita Chandra, Sergey Nejentsev, Alison M. Condliffe, Klaus Okkenhaug

ABSTRACT

Key PointsPI3Kδ (phosphoinositide 3-kinase-δ) is a key signal transduction node in cells of the immune system. This kinase complex is acutely activated in B cells and T cells after exposure to antigen and controls many aspects of lymphocyte development and differentiation, in part via the AKT, forkhead box O1 (FOXO1) and mechanistic target of rapamycin (mTOR) pathways.Rare loss-of-function mutations affecting PI3Kδ also cause immunodeficiency and immune-mediated pathologies, including colitis. The PI3Kδ inhibitor idelalisib frequently causes colitis at doses tested in leukaemia and lymphoma trials, possibly due to effects on regulatory T (Treg) cells.Activated PI3Kδ syndrome (APDS; also called PASLI disease) is a newly described primary immunodeficiency caused by hyperactive PI3Kδ signalling and resultant T cell senescence and/or death and impaired antibody responses. APDS is generally characterized by recurrent sinopulmonary infections with structural lung damage, viraemia with herpes family viruses, lymphoproliferative disease and increased risk of B cell malignancies.Patients with APDS1 have a heterozygous mutation in PIK3CD, the gene encoding the p110δ catalytic subunit of PI3Kδ, whereas APDS2 patients have a heterozygous mutation in PIK3R1, the gene encoding the p85α regulatory subunit of PI3Kδ. Both sets of mutations lead to higher intrinsic activity of PI3Kδ.To date, most patients with APDS have been treated with antibody replacement therapies and some have also been treated with the mTOR inhibitor rapamycin. In the future, PI3Kδ inhibitors may be used to treat these patients, possibly as the first example of targeted therapy against a hyperactive mutant kinase in primary immunodeficiency. More... »

PAGES

702-714

References to SciGraph publications

  • 2014-10-29. Gain of Function Mutations of PIK3CD as a Cause of Primary Sclerosing Cholangitis in JOURNAL OF CLINICAL IMMUNOLOGY
  • 2014-03-08. Mutations in PIK3CD Can Cause Hyper IgM Syndrome (HIGM) Associated with Increased Cancer Susceptibility in JOURNAL OF CLINICAL IMMUNOLOGY
  • 2009-06-21. mTOR regulates memory CD8 T cell differentiation in NATURE
  • 2015-12-10. Molecules in medicine mini-review: isoforms of PI3K in biology and disease in JOURNAL OF MOLECULAR MEDICINE
  • 2013-10-28. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency in NATURE IMMUNOLOGY
  • 2010-05-04. Regulatory Subunits of Class IA PI3K in PHOSPHOINOSITIDE 3-KINASE IN HEALTH AND DISEASE
  • 2005-12-28. Restoring function in exhausted CD8 T cells during chronic viral infection in NATURE
  • 2012-11-07. Novel Foxo1-dependent transcriptional programs control Treg cell function in NATURE
  • 2016-03-14. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells in NATURE MEDICINE
  • 2015-11-09. The cytotoxic T cell proteome and its shaping by mammalian Target of Rapamycin in NATURE IMMUNOLOGY
  • 2008-04-06. Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking in NATURE IMMUNOLOGY
  • 2011-02-27. The mammalian Target of Rapamycin (mTOR) regulates T helper cell differentiation through the selective activation of mTORC1 and mTORC2 signaling in NATURE IMMUNOLOGY
  • 2014-06-11. Inactivation of the PI3K p110δ breaks regulatory T cell-mediated immune tolerance to cancer in NATURE
  • 2016-04-13. Dominant Splice Site Mutations in PIK3R1 Cause Hyper IgM Syndrome, Lymphadenopathy and Short Stature in JOURNAL OF CLINICAL IMMUNOLOGY
  • 2012-10-19. Transcriptional control of effector and memory CD8+ T cell differentiation in NATURE REVIEWS IMMUNOLOGY
  • 2008-11-02. Distinct roles for Foxo1 at multiple stages of B cell differentiation in NATURE IMMUNOLOGY
  • 2012-09-30. The p110δ isoform of the kinase PI(3)K controls the subcellular compartmentalization of TLR4 signaling and protects from endotoxic shock in NATURE IMMUNOLOGY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/nri.2016.93

    DOI

    http://dx.doi.org/10.1038/nri.2016.93

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1041797827

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/27616589


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Immunology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cell Differentiation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cellular Senescence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Enzyme Activation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Gene Expression Regulation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immune System", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunity", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunologic Deficiency Syndromes", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Lymphocyte Activation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Lymphocytes", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Molecular Targeted Therapy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mutation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Phosphatidylinositol 3-Kinases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Phosphoinositide-3 Kinase Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Protein Subunits", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Signal Transduction", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Present address: Immunobiology Department, Yale University School of Medicine, New Haven, Connecticut 06511, USA.", 
              "id": "http://www.grid.ac/institutes/grid.47100.32", 
              "name": [
                "Molecular Development of the Immune System Section, Laboratory of Immunology, and Clinical Genomics Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 20892, Bethesda, Maryland, USA", 
                "Present address: Immunobiology Department, Yale University School of Medicine, New Haven, Connecticut 06511, USA."
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lucas", 
            "givenName": "Carrie L.", 
            "id": "sg:person.01244506520.85", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244506520.85"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medicine, University of Cambridge, CB2 0QQ, Cambridge, UK", 
              "id": "http://www.grid.ac/institutes/grid.5335.0", 
              "name": [
                "Laboratory of Lymphocyte Signalling and Development, Babraham Institute, CB22 3AT, Cambridge, UK", 
                "Department of Medicine, University of Cambridge, CB2 0QQ, Cambridge, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Chandra", 
            "givenName": "Anita", 
            "id": "sg:person.01026403066.64", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026403066.64"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medicine, University of Cambridge, CB2 0QQ, Cambridge, UK", 
              "id": "http://www.grid.ac/institutes/grid.5335.0", 
              "name": [
                "Department of Medicine, University of Cambridge, CB2 0QQ, Cambridge, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Nejentsev", 
            "givenName": "Sergey", 
            "id": "sg:person.01334150044.66", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334150044.66"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, S10 2RX, Sheffield, UK", 
              "id": "http://www.grid.ac/institutes/grid.11835.3e", 
              "name": [
                "Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, S10 2RX, Sheffield, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Condliffe", 
            "givenName": "Alison M.", 
            "id": "sg:person.01161633171.28", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01161633171.28"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Laboratory of Lymphocyte Signalling and Development, Babraham Institute, CB22 3AT, Cambridge, UK", 
              "id": "http://www.grid.ac/institutes/grid.418195.0", 
              "name": [
                "Laboratory of Lymphocyte Signalling and Development, Babraham Institute, CB22 3AT, Cambridge, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Okkenhaug", 
            "givenName": "Klaus", 
            "id": "sg:person.01356616513.06", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356616513.06"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/82_2010_39", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021130015", 
              "https://doi.org/10.1007/82_2010_39"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm.4062", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025304169", 
              "https://doi.org/10.1038/nm.4062"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10875-014-0109-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016127434", 
              "https://doi.org/10.1007/s10875-014-0109-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ni.2771", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012593761", 
              "https://doi.org/10.1038/ni.2771"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature11581", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1002551801", 
              "https://doi.org/10.1038/nature11581"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ni.1603", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014793117", 
              "https://doi.org/10.1038/ni.1603"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ni.3314", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1053085456", 
              "https://doi.org/10.1038/ni.3314"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ni.2005", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035267474", 
              "https://doi.org/10.1038/ni.2005"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10875-014-0012-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025974178", 
              "https://doi.org/10.1007/s10875-014-0012-9"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10875-016-0281-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035949698", 
              "https://doi.org/10.1007/s10875-016-0281-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature04444", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018989545", 
              "https://doi.org/10.1038/nature04444"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ni.1667", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038268281", 
              "https://doi.org/10.1038/ni.1667"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature13444", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027340229", 
              "https://doi.org/10.1038/nature13444"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ni.2426", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043371002", 
              "https://doi.org/10.1038/ni.2426"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature08155", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003181272", 
              "https://doi.org/10.1038/nature08155"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00109-015-1352-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1053726121", 
              "https://doi.org/10.1007/s00109-015-1352-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nri3307", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016124947", 
              "https://doi.org/10.1038/nri3307"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2016-09-12", 
        "datePublishedReg": "2016-09-12", 
        "description": "Key PointsPI3K\u03b4 (phosphoinositide 3-kinase-\u03b4) is a key signal transduction node in cells of the immune system. This kinase complex is acutely activated in B cells and T cells after exposure to antigen and controls many aspects of lymphocyte development and differentiation, in part via the AKT, forkhead box O1 (FOXO1) and mechanistic target of rapamycin (mTOR) pathways.Rare loss-of-function mutations affecting PI3K\u03b4 also cause immunodeficiency and immune-mediated pathologies, including colitis. The PI3K\u03b4 inhibitor idelalisib frequently causes colitis at doses tested in leukaemia and lymphoma trials, possibly due to effects on regulatory T (Treg) cells.Activated PI3K\u03b4 syndrome (APDS; also called PASLI disease) is a newly described primary immunodeficiency caused by hyperactive PI3K\u03b4 signalling and resultant T cell senescence and/or death and impaired antibody responses. APDS is generally characterized by recurrent sinopulmonary infections with structural lung damage, viraemia with herpes family viruses, lymphoproliferative disease and increased risk of B cell malignancies.Patients with APDS1 have a heterozygous mutation in PIK3CD, the gene encoding the p110\u03b4 catalytic subunit of PI3K\u03b4, whereas APDS2 patients have a heterozygous mutation in PIK3R1, the gene encoding the p85\u03b1 regulatory subunit of PI3K\u03b4. Both sets of mutations lead to higher intrinsic activity of PI3K\u03b4.To date, most patients with APDS have been treated with antibody replacement therapies and some have also been treated with the mTOR inhibitor rapamycin. In the future, PI3K\u03b4 inhibitors may be used to treat these patients, possibly as the first example of targeted therapy against a hyperactive mutant kinase in primary immunodeficiency.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/nri.2016.93", 
        "inLanguage": "en", 
        "isAccessibleForFree": true, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.2777680", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.3635849", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.3783467", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.5475983", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.4849827", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.2693078", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.4106881", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.2784635", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.2756589", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1029717", 
            "issn": [
              "1474-1733", 
              "1474-1741"
            ], 
            "name": "Nature Reviews Immunology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "11", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "16"
          }
        ], 
        "keywords": [
          "primary immunodeficiency", 
          "structural lung damage", 
          "antibody replacement therapy", 
          "heterozygous mutations", 
          "recurrent sinopulmonary infections", 
          "PI3K\u03b4 inhibitor idelalisib", 
          "herpes family viruses", 
          "mTOR inhibitor rapamycin", 
          "PI3K\u03b4 syndrome", 
          "most patients", 
          "lung damage", 
          "lymphoma trials", 
          "sinopulmonary infections", 
          "lymphoproliferative disease", 
          "replacement therapy", 
          "antibody response", 
          "inhibitor idelalisib", 
          "cell malignancies", 
          "immune system", 
          "patients", 
          "immunodeficiency", 
          "p110\u03b4 catalytic subunit", 
          "PI3K\u03b4 inhibitors", 
          "rare loss", 
          "PI3K\u03b4", 
          "lymphocyte development", 
          "box O1", 
          "rapamycin (mTOR) pathway", 
          "inhibitor rapamycin", 
          "colitis", 
          "mechanistic target", 
          "cell senescence", 
          "therapy", 
          "function mutations", 
          "intrinsic activity", 
          "cells", 
          "p85\u03b1 regulatory subunit", 
          "high intrinsic activity", 
          "mutations", 
          "APDS1", 
          "viraemia", 
          "idelalisib", 
          "malignancy", 
          "syndrome", 
          "leukemia", 
          "infection", 
          "antigen", 
          "doses", 
          "disease", 
          "pathology", 
          "trials", 
          "death", 
          "virus", 
          "risk", 
          "Akt", 
          "PIK3R1", 
          "rapamycin", 
          "inhibitors", 
          "exposure", 
          "PIK3CD", 
          "mutant kinases", 
          "genes", 
          "kinase complex", 
          "response", 
          "damage", 
          "pathway", 
          "subunits", 
          "differentiation", 
          "kinase", 
          "target", 
          "activity", 
          "catalytic subunit", 
          "O1", 
          "set of mutations", 
          "APDs", 
          "loss", 
          "date", 
          "senescence", 
          "effect", 
          "regulatory subunit", 
          "development", 
          "nodes", 
          "aspects", 
          "part", 
          "future", 
          "complexes", 
          "system", 
          "first example", 
          "set", 
          "example", 
          "Key PointsPI3K\u03b4", 
          "PointsPI3K\u03b4", 
          "key signal transduction node", 
          "signal transduction node", 
          "transduction node", 
          "hyperactive PI3K\u03b4", 
          "family viruses", 
          "APDS2 patients", 
          "hyperactive mutant kinase"
        ], 
        "name": "PI3K\u03b4 and primary immunodeficiencies", 
        "pagination": "702-714", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1041797827"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/nri.2016.93"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "27616589"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/nri.2016.93", 
          "https://app.dimensions.ai/details/publication/pub.1041797827"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2021-12-01T19:37", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_708.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/nri.2016.93"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/nri.2016.93'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/nri.2016.93'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/nri.2016.93'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/nri.2016.93'


     

    This table displays all metadata directly associated to this object as RDF triples.

    354 TRIPLES      22 PREDICATES      159 URIs      134 LITERALS      24 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/nri.2016.93 schema:about N18611f03f71441f5acae792cd0870434
    2 N1c5656538a044923850b087242658bb1
    3 N2127b10604724d38b2c10bfb845bad78
    4 N26a08eefd626461a8b34cb7185631a8c
    5 N56d0abe0060f47df89461d838e1ff1d5
    6 N621b0020f3f2450c9dea7fe5fa63034e
    7 N6740b6d460ed4ebe89bbf5521846d970
    8 N764141cc705b4edbb152e742c1d9f74e
    9 N7c1785eb6b4342088178744bb263c2ed
    10 N89bc43d9a7444fc0b36207f1719b563f
    11 Na1323585c0364e5ea1c652b3d6fb0864
    12 Na334071ab7964c26a684cfe4b670f36e
    13 Nb5c3a4a07ecf4c958820a5574f3372e0
    14 Ne2950f9dba17447d8f3449678a5e8ea4
    15 Ne336d7146d484cc98a30e03cca1404fd
    16 Ne7e0dc6f8efd4f7b8ead3923ff9d6244
    17 Nfec98ba729764b6e923022491682c4bd
    18 anzsrc-for:11
    19 anzsrc-for:1107
    20 schema:author N465001e361494538a66b27512568dfd0
    21 schema:citation sg:pub.10.1007/82_2010_39
    22 sg:pub.10.1007/s00109-015-1352-5
    23 sg:pub.10.1007/s10875-014-0012-9
    24 sg:pub.10.1007/s10875-014-0109-1
    25 sg:pub.10.1007/s10875-016-0281-6
    26 sg:pub.10.1038/nature04444
    27 sg:pub.10.1038/nature08155
    28 sg:pub.10.1038/nature11581
    29 sg:pub.10.1038/nature13444
    30 sg:pub.10.1038/ni.1603
    31 sg:pub.10.1038/ni.1667
    32 sg:pub.10.1038/ni.2005
    33 sg:pub.10.1038/ni.2426
    34 sg:pub.10.1038/ni.2771
    35 sg:pub.10.1038/ni.3314
    36 sg:pub.10.1038/nm.4062
    37 sg:pub.10.1038/nri3307
    38 schema:datePublished 2016-09-12
    39 schema:datePublishedReg 2016-09-12
    40 schema:description Key PointsPI3Kδ (phosphoinositide 3-kinase-δ) is a key signal transduction node in cells of the immune system. This kinase complex is acutely activated in B cells and T cells after exposure to antigen and controls many aspects of lymphocyte development and differentiation, in part via the AKT, forkhead box O1 (FOXO1) and mechanistic target of rapamycin (mTOR) pathways.Rare loss-of-function mutations affecting PI3Kδ also cause immunodeficiency and immune-mediated pathologies, including colitis. The PI3Kδ inhibitor idelalisib frequently causes colitis at doses tested in leukaemia and lymphoma trials, possibly due to effects on regulatory T (Treg) cells.Activated PI3Kδ syndrome (APDS; also called PASLI disease) is a newly described primary immunodeficiency caused by hyperactive PI3Kδ signalling and resultant T cell senescence and/or death and impaired antibody responses. APDS is generally characterized by recurrent sinopulmonary infections with structural lung damage, viraemia with herpes family viruses, lymphoproliferative disease and increased risk of B cell malignancies.Patients with APDS1 have a heterozygous mutation in PIK3CD, the gene encoding the p110δ catalytic subunit of PI3Kδ, whereas APDS2 patients have a heterozygous mutation in PIK3R1, the gene encoding the p85α regulatory subunit of PI3Kδ. Both sets of mutations lead to higher intrinsic activity of PI3Kδ.To date, most patients with APDS have been treated with antibody replacement therapies and some have also been treated with the mTOR inhibitor rapamycin. In the future, PI3Kδ inhibitors may be used to treat these patients, possibly as the first example of targeted therapy against a hyperactive mutant kinase in primary immunodeficiency.
    41 schema:genre article
    42 schema:inLanguage en
    43 schema:isAccessibleForFree true
    44 schema:isPartOf N94a62f2aba43407cbf5e31d916514d0f
    45 Na19dff956dee4540b8b036fc62e2887c
    46 sg:journal.1029717
    47 schema:keywords APDS1
    48 APDS2 patients
    49 APDs
    50 Akt
    51 Key PointsPI3Kδ
    52 O1
    53 PI3Kδ
    54 PI3Kδ inhibitor idelalisib
    55 PI3Kδ inhibitors
    56 PI3Kδ syndrome
    57 PIK3CD
    58 PIK3R1
    59 PointsPI3Kδ
    60 activity
    61 antibody replacement therapy
    62 antibody response
    63 antigen
    64 aspects
    65 box O1
    66 catalytic subunit
    67 cell malignancies
    68 cell senescence
    69 cells
    70 colitis
    71 complexes
    72 damage
    73 date
    74 death
    75 development
    76 differentiation
    77 disease
    78 doses
    79 effect
    80 example
    81 exposure
    82 family viruses
    83 first example
    84 function mutations
    85 future
    86 genes
    87 herpes family viruses
    88 heterozygous mutations
    89 high intrinsic activity
    90 hyperactive PI3Kδ
    91 hyperactive mutant kinase
    92 idelalisib
    93 immune system
    94 immunodeficiency
    95 infection
    96 inhibitor idelalisib
    97 inhibitor rapamycin
    98 inhibitors
    99 intrinsic activity
    100 key signal transduction node
    101 kinase
    102 kinase complex
    103 leukemia
    104 loss
    105 lung damage
    106 lymphocyte development
    107 lymphoma trials
    108 lymphoproliferative disease
    109 mTOR inhibitor rapamycin
    110 malignancy
    111 mechanistic target
    112 most patients
    113 mutant kinases
    114 mutations
    115 nodes
    116 p110δ catalytic subunit
    117 p85α regulatory subunit
    118 part
    119 pathology
    120 pathway
    121 patients
    122 primary immunodeficiency
    123 rapamycin
    124 rapamycin (mTOR) pathway
    125 rare loss
    126 recurrent sinopulmonary infections
    127 regulatory subunit
    128 replacement therapy
    129 response
    130 risk
    131 senescence
    132 set
    133 set of mutations
    134 signal transduction node
    135 sinopulmonary infections
    136 structural lung damage
    137 subunits
    138 syndrome
    139 system
    140 target
    141 therapy
    142 transduction node
    143 trials
    144 viraemia
    145 virus
    146 schema:name PI3Kδ and primary immunodeficiencies
    147 schema:pagination 702-714
    148 schema:productId N4c1a621a626645e4beeb767be983574e
    149 N4f19dc432aa6498c918f018bf1cd0581
    150 Na050e2ddf616404b9f07bff3a234eda4
    151 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041797827
    152 https://doi.org/10.1038/nri.2016.93
    153 schema:sdDatePublished 2021-12-01T19:37
    154 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    155 schema:sdPublisher N27752c56dd274f12894ff66fa732f099
    156 schema:url https://doi.org/10.1038/nri.2016.93
    157 sgo:license sg:explorer/license/
    158 sgo:sdDataset articles
    159 rdf:type schema:ScholarlyArticle
    160 N18611f03f71441f5acae792cd0870434 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    161 schema:name Phosphatidylinositol 3-Kinases
    162 rdf:type schema:DefinedTerm
    163 N1c5656538a044923850b087242658bb1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    164 schema:name Cell Differentiation
    165 rdf:type schema:DefinedTerm
    166 N2127b10604724d38b2c10bfb845bad78 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    167 schema:name Lymphocyte Activation
    168 rdf:type schema:DefinedTerm
    169 N26a08eefd626461a8b34cb7185631a8c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    170 schema:name Enzyme Activation
    171 rdf:type schema:DefinedTerm
    172 N27752c56dd274f12894ff66fa732f099 schema:name Springer Nature - SN SciGraph project
    173 rdf:type schema:Organization
    174 N465001e361494538a66b27512568dfd0 rdf:first sg:person.01244506520.85
    175 rdf:rest Nd4281652bf9b45a89ff644a96a615077
    176 N4c1a621a626645e4beeb767be983574e schema:name pubmed_id
    177 schema:value 27616589
    178 rdf:type schema:PropertyValue
    179 N4f19dc432aa6498c918f018bf1cd0581 schema:name dimensions_id
    180 schema:value pub.1041797827
    181 rdf:type schema:PropertyValue
    182 N56d0abe0060f47df89461d838e1ff1d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    183 schema:name Cellular Senescence
    184 rdf:type schema:DefinedTerm
    185 N621b0020f3f2450c9dea7fe5fa63034e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    186 schema:name Lymphocytes
    187 rdf:type schema:DefinedTerm
    188 N6740b6d460ed4ebe89bbf5521846d970 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    189 schema:name Phosphoinositide-3 Kinase Inhibitors
    190 rdf:type schema:DefinedTerm
    191 N6d8eead9d47a4fc88cc423295e2f7caa rdf:first sg:person.01161633171.28
    192 rdf:rest N7a963c6eb51d4652af9c1786612e4da5
    193 N764141cc705b4edbb152e742c1d9f74e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    194 schema:name Mutation
    195 rdf:type schema:DefinedTerm
    196 N7a963c6eb51d4652af9c1786612e4da5 rdf:first sg:person.01356616513.06
    197 rdf:rest rdf:nil
    198 N7c1785eb6b4342088178744bb263c2ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    199 schema:name Immunologic Deficiency Syndromes
    200 rdf:type schema:DefinedTerm
    201 N89bc43d9a7444fc0b36207f1719b563f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    202 schema:name Signal Transduction
    203 rdf:type schema:DefinedTerm
    204 N94a62f2aba43407cbf5e31d916514d0f schema:volumeNumber 16
    205 rdf:type schema:PublicationVolume
    206 Na050e2ddf616404b9f07bff3a234eda4 schema:name doi
    207 schema:value 10.1038/nri.2016.93
    208 rdf:type schema:PropertyValue
    209 Na1323585c0364e5ea1c652b3d6fb0864 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    210 schema:name Humans
    211 rdf:type schema:DefinedTerm
    212 Na19dff956dee4540b8b036fc62e2887c schema:issueNumber 11
    213 rdf:type schema:PublicationIssue
    214 Na334071ab7964c26a684cfe4b670f36e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    215 schema:name Animals
    216 rdf:type schema:DefinedTerm
    217 Nb5c3a4a07ecf4c958820a5574f3372e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    218 schema:name Gene Expression Regulation
    219 rdf:type schema:DefinedTerm
    220 Nc628c08217054e1f81a6a254545819c5 rdf:first sg:person.01334150044.66
    221 rdf:rest N6d8eead9d47a4fc88cc423295e2f7caa
    222 Nd4281652bf9b45a89ff644a96a615077 rdf:first sg:person.01026403066.64
    223 rdf:rest Nc628c08217054e1f81a6a254545819c5
    224 Ne2950f9dba17447d8f3449678a5e8ea4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    225 schema:name Immune System
    226 rdf:type schema:DefinedTerm
    227 Ne336d7146d484cc98a30e03cca1404fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    228 schema:name Protein Subunits
    229 rdf:type schema:DefinedTerm
    230 Ne7e0dc6f8efd4f7b8ead3923ff9d6244 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    231 schema:name Immunity
    232 rdf:type schema:DefinedTerm
    233 Nfec98ba729764b6e923022491682c4bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    234 schema:name Molecular Targeted Therapy
    235 rdf:type schema:DefinedTerm
    236 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    237 schema:name Medical and Health Sciences
    238 rdf:type schema:DefinedTerm
    239 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
    240 schema:name Immunology
    241 rdf:type schema:DefinedTerm
    242 sg:grant.2693078 http://pending.schema.org/fundedItem sg:pub.10.1038/nri.2016.93
    243 rdf:type schema:MonetaryGrant
    244 sg:grant.2756589 http://pending.schema.org/fundedItem sg:pub.10.1038/nri.2016.93
    245 rdf:type schema:MonetaryGrant
    246 sg:grant.2777680 http://pending.schema.org/fundedItem sg:pub.10.1038/nri.2016.93
    247 rdf:type schema:MonetaryGrant
    248 sg:grant.2784635 http://pending.schema.org/fundedItem sg:pub.10.1038/nri.2016.93
    249 rdf:type schema:MonetaryGrant
    250 sg:grant.3635849 http://pending.schema.org/fundedItem sg:pub.10.1038/nri.2016.93
    251 rdf:type schema:MonetaryGrant
    252 sg:grant.3783467 http://pending.schema.org/fundedItem sg:pub.10.1038/nri.2016.93
    253 rdf:type schema:MonetaryGrant
    254 sg:grant.4106881 http://pending.schema.org/fundedItem sg:pub.10.1038/nri.2016.93
    255 rdf:type schema:MonetaryGrant
    256 sg:grant.4849827 http://pending.schema.org/fundedItem sg:pub.10.1038/nri.2016.93
    257 rdf:type schema:MonetaryGrant
    258 sg:grant.5475983 http://pending.schema.org/fundedItem sg:pub.10.1038/nri.2016.93
    259 rdf:type schema:MonetaryGrant
    260 sg:journal.1029717 schema:issn 1474-1733
    261 1474-1741
    262 schema:name Nature Reviews Immunology
    263 schema:publisher Springer Nature
    264 rdf:type schema:Periodical
    265 sg:person.01026403066.64 schema:affiliation grid-institutes:grid.5335.0
    266 schema:familyName Chandra
    267 schema:givenName Anita
    268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026403066.64
    269 rdf:type schema:Person
    270 sg:person.01161633171.28 schema:affiliation grid-institutes:grid.11835.3e
    271 schema:familyName Condliffe
    272 schema:givenName Alison M.
    273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01161633171.28
    274 rdf:type schema:Person
    275 sg:person.01244506520.85 schema:affiliation grid-institutes:grid.47100.32
    276 schema:familyName Lucas
    277 schema:givenName Carrie L.
    278 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244506520.85
    279 rdf:type schema:Person
    280 sg:person.01334150044.66 schema:affiliation grid-institutes:grid.5335.0
    281 schema:familyName Nejentsev
    282 schema:givenName Sergey
    283 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334150044.66
    284 rdf:type schema:Person
    285 sg:person.01356616513.06 schema:affiliation grid-institutes:grid.418195.0
    286 schema:familyName Okkenhaug
    287 schema:givenName Klaus
    288 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356616513.06
    289 rdf:type schema:Person
    290 sg:pub.10.1007/82_2010_39 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021130015
    291 https://doi.org/10.1007/82_2010_39
    292 rdf:type schema:CreativeWork
    293 sg:pub.10.1007/s00109-015-1352-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053726121
    294 https://doi.org/10.1007/s00109-015-1352-5
    295 rdf:type schema:CreativeWork
    296 sg:pub.10.1007/s10875-014-0012-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025974178
    297 https://doi.org/10.1007/s10875-014-0012-9
    298 rdf:type schema:CreativeWork
    299 sg:pub.10.1007/s10875-014-0109-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016127434
    300 https://doi.org/10.1007/s10875-014-0109-1
    301 rdf:type schema:CreativeWork
    302 sg:pub.10.1007/s10875-016-0281-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035949698
    303 https://doi.org/10.1007/s10875-016-0281-6
    304 rdf:type schema:CreativeWork
    305 sg:pub.10.1038/nature04444 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018989545
    306 https://doi.org/10.1038/nature04444
    307 rdf:type schema:CreativeWork
    308 sg:pub.10.1038/nature08155 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003181272
    309 https://doi.org/10.1038/nature08155
    310 rdf:type schema:CreativeWork
    311 sg:pub.10.1038/nature11581 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002551801
    312 https://doi.org/10.1038/nature11581
    313 rdf:type schema:CreativeWork
    314 sg:pub.10.1038/nature13444 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027340229
    315 https://doi.org/10.1038/nature13444
    316 rdf:type schema:CreativeWork
    317 sg:pub.10.1038/ni.1603 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014793117
    318 https://doi.org/10.1038/ni.1603
    319 rdf:type schema:CreativeWork
    320 sg:pub.10.1038/ni.1667 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038268281
    321 https://doi.org/10.1038/ni.1667
    322 rdf:type schema:CreativeWork
    323 sg:pub.10.1038/ni.2005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035267474
    324 https://doi.org/10.1038/ni.2005
    325 rdf:type schema:CreativeWork
    326 sg:pub.10.1038/ni.2426 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043371002
    327 https://doi.org/10.1038/ni.2426
    328 rdf:type schema:CreativeWork
    329 sg:pub.10.1038/ni.2771 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012593761
    330 https://doi.org/10.1038/ni.2771
    331 rdf:type schema:CreativeWork
    332 sg:pub.10.1038/ni.3314 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053085456
    333 https://doi.org/10.1038/ni.3314
    334 rdf:type schema:CreativeWork
    335 sg:pub.10.1038/nm.4062 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025304169
    336 https://doi.org/10.1038/nm.4062
    337 rdf:type schema:CreativeWork
    338 sg:pub.10.1038/nri3307 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016124947
    339 https://doi.org/10.1038/nri3307
    340 rdf:type schema:CreativeWork
    341 grid-institutes:grid.11835.3e schema:alternateName Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, S10 2RX, Sheffield, UK
    342 schema:name Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, S10 2RX, Sheffield, UK
    343 rdf:type schema:Organization
    344 grid-institutes:grid.418195.0 schema:alternateName Laboratory of Lymphocyte Signalling and Development, Babraham Institute, CB22 3AT, Cambridge, UK
    345 schema:name Laboratory of Lymphocyte Signalling and Development, Babraham Institute, CB22 3AT, Cambridge, UK
    346 rdf:type schema:Organization
    347 grid-institutes:grid.47100.32 schema:alternateName Present address: Immunobiology Department, Yale University School of Medicine, New Haven, Connecticut 06511, USA.
    348 schema:name Molecular Development of the Immune System Section, Laboratory of Immunology, and Clinical Genomics Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 20892, Bethesda, Maryland, USA
    349 Present address: Immunobiology Department, Yale University School of Medicine, New Haven, Connecticut 06511, USA.
    350 rdf:type schema:Organization
    351 grid-institutes:grid.5335.0 schema:alternateName Department of Medicine, University of Cambridge, CB2 0QQ, Cambridge, UK
    352 schema:name Department of Medicine, University of Cambridge, CB2 0QQ, Cambridge, UK
    353 Laboratory of Lymphocyte Signalling and Development, Babraham Institute, CB22 3AT, Cambridge, UK
    354 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...